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Treatment with the SGLT2 inhibitor 
luseogliflozin improves nonalcoholic 
steatohepatitis in a rodent model with diabetes 
mellitus
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Abstract 
Background: Insulin resistance with elevated glucose is a risk factor for non-alcoholic steatohepatitis (NASH). We 
investigated the effects of the sodium glucose cotransporter 2 (SGLT2) inhibitor luseogliflozin on NASH development 
using a rodent model.
Methods: Mice were treated with both nicotinamide and streptozotocin (NA/STZ) to reduce insulin secretory 
capacity, and then fed a high fat diet containing trans fatty acids (HFDT) for 8 weeks. The NA/STZ HFDT-fed mice were 
divided into two groups, either treated with luseogliflozin or untreated, during this period. The glucose elevations 
in the NA/STZ-treated and HFDT-fed mice were significantly improved by luseogliflozin administration. While HFDT 
feeding induced NASH development as shown by liver weight gain with lipid accumulation and increased serum 
alanine aminotransferase, these changes were all attenuated in the group treated with luseogliflozin. In addition, 
fibrotic change and increases in collagen deposition with upregulations of collagen1 and smooth muscle actin and 
inflammatory cytokine expressions observed in the HFDT-fed mouse livers were also normalized by luseogliflozin 
administration.
Conclusions: Taken together, these results obtained in mice demonstrate the favorable effects of administering 
SGLT2 inhibitors, for the treatment of NASH associated with diabetes mellitus. We anticipate that these agents would 
be applicable to humans.
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Background
Recent advances in the development of anti-diabetic 
drugs have provided numerous therapeutic options for 
patients with Type 2 diabetes mellitus (T2DM) [1–4]. 
Among various anti-diabetic drugs, sodium glucose 
cotransporter 2 (SGLT2) inhibitors are unique in terms of 
their mechanism of action. These drugs increase urinary 
glucose excretion, thereby lowering the blood glucose 
concentration [1, 5–10]. A number of previous studies, 
using rodent models, demonstrated that several of these 
SGLT2 inhibitors can ameliorate fatty liver with signifi-
cant body weight loss, and the weight reducing effects of 
various SGLT2 inhibitors have also been documented in 
humans [11].
Nevertheless, to our knowledge, only one study to date 
has investigated the effects of a SGLT2 inhibitor on non-
alcoholic steatohepatitis (NASH) development. In that 
study, ipragliflozin, a SGLT2 inhibitor, failed to reverse 
inflammation and raised both the alanine aminotrans-
ferase (ALT) and the aspartate aminotransferase  (AST) 
level, despite only a slight reduction in hepatic lipid 
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accumulation, in methionine choline diet (MCD)-
induced NASH model rats [5].
Herein, we prepared a rodent model suffering from 
both DM and NASH, and obtained evidence that luse-
ogliflozin exerts a strong protective effect against the 
development of NASH induced by a high fat diet con-
taining trans fatty acids (HFDT).
Methods
Animals, diets and luseogliflozin treatment
To induce mild to moderate diabetes in C57BL/6 mice, 
nicotinamide (NA) (120 mg/kg) and then streptozotocin 
(STZ) (100 mg/kg) was injected after starvation for 20 h, 
as shown in Fig. 1a. The mice were given a normal chow 
diet (ND) (Oriental Yeast, Tokyo, Japan) for 1 week as an 
acclimatization period, and then fed a ND or a diet with 
a high fat (40 % of kcal), high fructose (22 % by wt), and 
high cholesterol (2  % by wt) composition, wherein the 
fat source was trans-fat (Primex partially hydrogenated 
vegetable oil shortening, cat. no. D09100301, Research 
Diet, New Brunswick, USA). Luseogliflozin [TS-071: 
(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-
methylphenyl]-1-thio-d-glucitol], a SGLT2 inhibitor [12] 
synthesized by Taisho Pharmaceutical Co., Ltd. was given 
to half of the NA/STZ-treated and half of the HFDT-
fed mice by mixing it into their food at a concentration 
of 0.1 %. This was done because the preliminary experi-
ments suggested the maximal hypoglycemic effect to be 
obtained at 0.1 % (data not shown). As controls for this 
study, we used non-treated C57BL/6J mice fed the ND. 
All animals were handled in accordance with the Guide-
lines for the Care and Use of Experimental animals pub-
lished by Hiroshima University.
Histochemical studies
Paraffin-embedded liver sections were stained with 
hematoxylin and eosin for quantification of steatosis, fat 
droplets and inflammation of hepatic tissue. For detec-
tion of collagen deposition, deparaffinized sections were 
submerged in Sirius red solution.
For α-smooth muscle actin (SMA) staining, deparaffi-
nized sections were permeabilized in 0.1 % Triton solu-
tion and heated in 10  mM citrate (pH 6.0). After being 
washed, the sections were incubated with SMA antibody 
Fig. 1 Luseogliflozin improved elevated glucose concentrations and normalized HFDT feeding-induced hepatosteatosis. a Control, NA/STZ/HFDT 
and NA/STZ/HFDT/Luseo mice. b, c Blood glucose and insulin concentrations in fasted states. d Whole body and liver weights. e Serum ALT level. f 
Serum triglyceride, cholesterol and non-esterified fatty acids (NEFA) levels. All data are shown as means + SEM
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(1:500) at 4 °C overnight. The slides were then visualized 
by the diaminobenzidine method.
For Oil Red O staining to examine triglyceride accu-
mulation, livers were frozen in liquid nitrogen and 
embedded in OTC (optimum cutting temperature) com-
pound. After staining, these sections were washed and 
embedded.
Measurements of serum parameters and hepatic 
triglyceride, cholesterol and non‑esterified fatty acids 
(NEFAs)
Serum insulin and ALT levels were assayed with the 
Ultra-sensitive mouse insulin Elisa kit (Morinaga Yoko-
hama, Japan) and the Transaminase C-II Test Wako kit 
(Wako, Osaka, Japan), respectively. Triglycerides, cho-
lesterol and NEFAs in the livers were measured with the 
triglyceride E-test (Wako Osaka, Japan), T-choE (Wako) 
and NEFA C test (Wako) kits, respectively.
Quantitative real time reverse transcription PCR
Total RNA was extracted from mouse livers using Sep-
asol reagent (Nakalai Tesche, Kyoto, Japan). Template 
cDNA was obtained using total RNA employing a Verso 
cDNA synthesis kit (Thermo Scientific), and quantita-
tive real time PCR was carried out using SYBR Green 
PCR master mix (Invitrogen, Tokyo, Japan). The designed 
primers were as follows; Collagen1a1 (F: GAGCGGAGA 
GTACTGGATCG R: GCTTCTTTTCCTTGGGGTTC), 
Collagen1a2 (F: CCGTGCTTCTCAGAACATCA 
R: GAGCAGCCATCGACTAGGAC), SMA (F: 
ACCAACTGGGACGACATGGAA R: TGTCAGCAGT 
GTCGGATGCTC), tissue inhibitor of metalloproteinase 
1 (TIMP1) (F: ATTCAAGGCTGTGGGAATG R: CTCA 
GAGTACGCCAGGGAAC), monocyte chemotactic pro-
tein-1 (MCP-1) (F: AGGTCCCTGTCATGCTTCTG R: 
TCTGGACCCATTCCTTCTTG), interleukin-1β [inter-
leukin (IL)-1 β] F: TGGGCCTCAAAGGAAAGAAT 
R: CTTGGGATCCACACTCTCCA), IL-6 (F: CCATC 
CAGTTGCCTTCTTGG R: TCCACGATTTCCCAGA 
GAACA), IL-12 (F: TGGAGCACTCCCCATTCCTA 
R: TGAGCTTGCACGCAGACATT), transforming 
growth factor (TGF) (F: GGAAGGACCTGGGTTG 
GAAG R: GGACAACTGCTCCACCTTGG), F4/80 (F: 
TCTGGGGAGCTTACGATGGA R: TAGGAATCC 
CGCAATGATGG) AND GAPDH (F: TGATGGGTGT 
GAACCACGAG R: GGGCCATCCACAGTCTTCTG).
Statistical analysis
Results are expressed as mean  ±  SE. Statistical sig-
nificance was assessed using ANOVA followed by the 
Tukey HSD test. Values of p  <  0.05 were taken to indi-
cate a statistically significant difference. Due to software 
limitations, we gave p < 0.0001 whenever the p value was 
smaller than 0.0001.
Results
Mice were injected with both 120  mg/kg NA and 
100 mg/kg STZ twice, 2 days apart (Fig. 1a). Half of these 
mice were treated with luseogliflozin (NA/STZ/HFDT/
Luseo) and the other half was left untreated (NA/STZ/
HFDT). While the blood glucose levels of the control 
mice, not given NA, STZ, or luseogliflozin, receiving 
only the ND, remained at approximately 150 mg/dL for 
the entire 8 weeks, NA/STZ/HFDT mice showed eleva-
tions to between 230 and 410  mg/dL (Fig.  1b). In con-
trast, the blood glucose level of the NA/STZ/HFDT/
Luseo group was normalized to nearly that of the control 
group. The fasting serum insulin level of the NA/STZ/
HFDT mice was approximately 40  % of that in control 
mice, and did not differ from that of NA/STZ/HFDT/
Luseo mice (Fig.  1c). Interestingly, despite there being 
no significant differences in body weights among the 
three groups, liver weight and the serum ALT level were 
higher in the NA/STZ/HFDT than in the control mice, 
while showing normalization in the NA/STZ/HFDT/
Luseo group (Fig. 1d, e). On the other hand, serum tri-
glyceride and cholesterol levels were slightly higher in 
the NA/STZ/HFDT/Luseo than in the NA/STZ/HFDT 
group (Fig. 1f ).
Hematoxylin eosin staining of the livers from the con-
trol mice showed only modest steatosis. In contrast, the 
livers of NA/STZ/HFDT mice had developed marked 
macrovesicular steatosis, and the administration of luse-
ogliflozin reduced this steatosis (Fig. 2a). Consistent with 
the HE staining results, Oil Red O staining revealed that 
the livers of control mice had only sparse lipid droplets, 
while NA/STZ/HFDT mice showed abundant lipid drop-
lets. As expected, NA/STZ/HFDT/Luseo mice showed 
minimal lipid accumulation (Fig. 2b).
In contrast, the livers of NA/STZ/HFDT/Luseo mice 
showed much less hepatic accumulation of triglyceride, 
cholesterol and NEFA than those of the NA/STZ/HFDT 
mice not given luseogliflozin (Fig.  2d, e, f ). Sirius red 
staining revealed marked liver fibrosis in the NA/STZ/
HFDT mice, while there was almost no collagen deposi-
tion in the livers of NA/STZ/HFDT/Luseo mice (Fig. 2c). 
Consistent with the results of Sirius red staining, marked 
increases in mRNA expressions of collagen1a1/1a2 in the 
NA/STZ/HFDT mice as compared with the control mice, 
were partially but significantly normalized by luseogliflo-
zin treatment (NA/STZ/HFDT/Luseo) (Fig. 2g). The TGF 
mRNA level was also elevated in the NA/STZ/HFDT 
mice, but showed normalization in the NA/STZ/HFDT/
Luseo mice (Fig. 2g).
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Since activation of hepatic stellate cells reportedly plays 
a critical role in the development of hepatic fibrosis [13, 
14], immunofluorescence staining was carried out using 
anti-SMA antibody. Although the livers of control mice 
had few SMA-positive cells, numerous SMA positive 
cells were observed in the livers of HFDT-fed mice, and 
this finding was normalized by luseogliflozin administra-
tion (Fig. 3a). These immunochemical staining data were 
supported by the analysis of mRNA expressions of SMA 
and TIMP1, expressions of which were elevated in the 
NA/STZ/HFDT mice, but normalized in the NA/STZ/
HFDT/Luseo mice (Fig. 3b). The expressions of cytokines 
such as MCP-1, IL-1β, IL-6, IL-12 and F4/80 were also 
markedly elevated in the NA/STZ/HFDT mice, but nor-
malized in the NA/STZ/HFDT/Luseo mice (Fig.  3c). 
These results indicate that luseogliflozin treatment not 
only reduced lipid accumulation but also suppressed the 
inflammation in the livers of these mice.
Discussion
In this study, we endeavored to prepare model mice suf-
fering from both diabetes mellitus and NASH. As we pre-
viously found that blood glucose levels were raised only 
slightly by HFDT feeding, the mice in these experiments 
were treated with NA and STZ to moderately reduce 
insulin secretory capacity and thereby raise their blood 
glucose concentrations.
Our results using this diabetes plus NASH model 
showed clearly that luseogliflozin not only normalized 
elevated glucose concentrations, but also almost com-
pletely suppressed the development of NASH based 
on the histochemical findings, as well as measurements 
of hepatic lipid content and various serum parameters 
indicative of liver injury, fibrosis and inflammation. On 
the other hand, the NA/STZ/HFDT/Luseo group showed 
mild increases in serum TG and NEFA levels, as com-
pared to the NA/STZ/HFDT group.
Fig. 2 Luseogliflozin normalized HFDT feeding-induced hepatosteatosis and fibrosis. a–c Staining with HE, Oil red O and Sirius red, respectively. 
Representative photographs of each group are shown. d–f The amounts of triglyceride, cholesterol and NEFA in the livers. g mRNA levels of col-
lagen 1, collagen 2 and TGF. All data are shown as means + SEM
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This phenomenon might be attributable to increased 
expression levels of scavenger receptor CD36 in the liver. 
Indeed, CD36 expression levels in the NA/STZ/HFDT 
group were approximately triple those in the control 
group, but were normalized by luseogliflozin treatment 
(data not shown).
Therefore, the livers of NA/STZ/HFDT mice may vig-
orously take up lipids from blood, resulting in decreased 
of blood TG and NEFA levels.
Interestingly, despite liver weights being significantly 
reduced in the NA/STZ/HFDT/Luseo as compared 
with NA/STZ/HFDT mice, the overall reduction in 
body weight was very slight and did not reach statisti-
cal significance. One possible explanation of the effect 
of luseogliflozin on NASH would be that excessive lipid 
accumulation in the NASH liver might be preferentially 
reversed, or even catabolized, in the energy deficient state 
induced by luseogliflozin administration. Another pos-
sible mechanism involves glucagon. Very recently, it was 
reported that SGLT2 is expressed in glucagon-secreting 
α cells of pancreatic islets and that SGLT2 inhibitors thus 
promote glucagon secretion [8]. An increased serum 
glucagon concentration may be the key to liver-dominant 
reduction of lipid accumulation.
Fig. 3 Luseogliflozin suppresses HFDT-induced activation of hepatic stellate cells and inflammation in the liver. a Immunostaining with anti-SMA 
antibody, as a marker of stellate cell activation. Representative photographs of each group are shown. b mRNA levels of SMA and TIMP1. c The 
mRNA levels of MCP-1, IL-1β, IL-6 IL-12 and F4/80. All data are shown as means + SEM
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Regarding the pathogenesis of NASH, the “two-hit 
theory” has been proposed as a mechanism underlying 
the development of this disorder. The first and second 
hits involve simple steatosis, while factors such as oxida-
tive stress and inflammatory cytokines exacerbate NASH 
once it has developed [13, 15–18]. A previous study 
found that ipragliflozin had no significant effect on either 
inflammation or ALT and AST elevations in MCD diet-
induced NASH model rats [5]. Their results are obviously 
different from ours showing luseogliflozin administra-
tion to exert a favorable effect on both the first and the 
second hit. The MCD diet-induced NASH model show-
ing marked body weight loss is artificial, however, and 
does not reflect the pathogenesis of human NASH [19]. 
In addition, as the MCD diet fed mouse does not show 
glucose elevation or insulin resistance, it is not regarded 
as an appropriate model for investigating the effects of 
SGLT2 inhibitors. We consider beneficial SGLT2 inhibi-
tor effects to not be limited to the amelioration of stea-
tosis, with reductions in hepatic inflammation, cell death 
and fibrosis also being obtained, as indicated by our 
results.
Therefore, this is the first clear demonstration of the 
favorable effects of administering SGLT2 inhibitors, for 
the treatment of NASH accompanying diabetes mellitus, 
using a rodent model. We anticipate that a future clini-
cal study will demonstrate the usefulness, for treating 
NASH, of SGLT2 inhibitor agents.
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